Evidence map›Paper›PMID 30820552›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2019

Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death.

Mark Lambie, Lucy Teece, David W Johnson, Michaela Petrie, Robert Mactier, Ivonne Solis-Trapala, John Belcher, Hilary L Bekker, Martin Wilkie, Ken Tupling and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. The future of peritoneal dialysis.Clinical kidney journal · 2024
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Mark LambieInstitute for Applied Clinical Sciences, Keele University, Staffordshire, UK.
Lucy TeeceInstitute of Primary Care and Health Sciences, Keele University, Staffordshire, UK.
David W JohnsonDepartment of Nephrology, Princess Alexandra Hospital, Centre for Kidney Disease Research, University of Queensland, Brisbane, Australia.
Michaela PetrieRenal Unit, Edinburgh Royal Infirmary, NHS Lothian, Edinburgh, Scotland, UK.
Robert MactierRenal Services, Glasgow Royal Infirmary, Glasgow, Scotland, UK.
Ivonne Solis-TrapalaInstitute for Applied Clinical Sciences, Keele University, Staffordshire, UK.
John BelcherInstitute of Primary Care and Health Sciences, Keele University, Staffordshire, UK.
Hilary L BekkerLeeds Institute of Health Sciences, University of Leeds, Leeds, UK.
Martin WilkieRenal Unit, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Ken TuplingKidney Patient Association, Sheffield Area Kidney Association, Northern General Hospital, Sheffield, UK.
Louise Phillips-DarbyInstitute of Primary Care and Health Sciences, Keele University, Staffordshire, UK.
Simon J DaviesInstitute for Applied Clinical Sciences, Keele University, Staffordshire, UK.
Keele University · GBEdinburgh Royal Infirmary · GBGlasgow Royal Infirmary · GBNorthern General Hospital · GBSheffield Teaching Hospitals NHS Foundation Trust · GBThe University of Queensland · AUUniversity of Leeds · GB

Funding

Department of Health PB-PG-0610-22456
6 · The paper itself

Abstract

backgroundRisk of encapsulating peritoneal sclerosis (EPS) is strongly associated with the duration of peritoneal dialysis (PD), such that patients who have been on PD for some time may consider elective transfer to haemodialysis to mitigate the risk of EPS. There is a need to determine this risk to better inform clinical decision making, but previous studies have not allowed for the competing risk of death.

methodsThis study included new adult PD patients in Australia and New Zealand (ANZ; 1990-2010) or Scotland (2000-08) followed until 2012. Age, time on PD, primary renal disease, gender, data set and diabetic status were evaluated as predictors at the start of PD, then at 3 and 5 years after starting PD using flexible parametric competing risks models.

resultsIn 17 396 patients (16 162 ANZ, 1234 Scotland), EPS was observed in 99 (0.57%) patients, less frequently in ANZ patients (n = 65; 0.4%) than in Scottish patients (n = 34; 2.8%). The estimated risk of EPS was much lower when the competing risk of death was taken into account (1 Kaplan-Meier = 0.0126, cumulative incidence function = 0.0054). Strong predictors of EPS included age, primary renal disease and time on PD. The risk of EPS was reasonably discriminated at the start of PD (C-statistic = 0.74-0.79) and this improved at 3 and 5 years after starting PD (C-statistic = 0.81-0.92).

conclusionsEPS risk estimates are lower when calculated using competing risk of death analyses. A patient's estimated risk of EPS is country-specific and can be predicted using age, primary renal disease and duration of PD.

Indexed as

AdultAgedFemaleHumansMaleMiddle AgedNew ZealandPeritoneal DialysisPeritoneal DiseasesPrognosisRisk AssessmentRisk FactorsSclerosisScotlandSurvival Rateageencapsulating peritoneal sclerosisperitoneal dialysisperitoneal membraneprognosis

Identifiers

PMID30820552
PMCPMC6735880
OpenAlexW2918581721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.